Glembatumumab vedotin: Phase IIb started

Celldex began an open-label, U.S. Phase IIb trial in 120 patients evaluating 1.88 mg/kg IV glembatumumab vedotin given on day 1 of each 21-day cycle vs. single agent chemotherapy of the investigator's...